Last checked at 27 Jun 2023 08:21
GSK granted US FDA fast track for gonorrhoea vaccine
(Alliance News) - GSK PLC on Tuesday reported that the US Food & Drug Administration has granted its gonorrhoea investigational vaccine a "fast track" designation.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades8,131
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,529.50
Bid:
1,531.50
Ask:
1,532.00
Change:
3.50 (0.23%)
Spread:
0.50 (0.033%)
Open:
1,537.00
High:
1,541.50
Low:
1,523.00
Prev. Close:
1,526.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.GSK guidance looking 'increasingly challenging', says UBS
Thu, 17th Apr 2014 11:50
UBS has reduced its target price for GlaxoSmithKline (GSK) from 1,650p to 1,500p, saying that forecasts for earnings growth may continue to prove elusive for the pharmaceutical group."The prospect of earnings per share (EPS) growth has been delayed year after year at GSK. Consensus - as every year - continues to project growth from next year," UBS said."However, such acceleration seems increasingly unlikely in view of numerous headwinds (weak execution in respiratory, increasing competition in respiratory and oncology, uncertain outlook in emerging markets, negative mix effects, and addiction to non-recurring items)."The bank retained its 'neutral' recommendation, saying that guidance for 2014 "looks increasingly challenging".The launch of a generic version of Lovaza by Teva Pharmaceutical Industries this month will have reduced GSK's chances of reaching the upper end of its guidance for core EPS growth of 4-8% at constant currencies this year, UBS said.Meanwhile, US prescription trends in the first quarter suggest that "even the lower end may be tough to achieve".The bank has made 2-5% reductions to its EPS forecasts at GSK over 2014-2018. Its new estimates stand 10-15% below consensus forecasts "yet could still be too optimistic"."Consensus may be slow to reflect GSK's deteriorating growth outlook, but we expect this to become increasingly reflected in the multiple," UBS said. "It also added that dividend growth expectations going forward "might not be met".The stock was down 1% at 1,547.71p by 11:49.BC
More News
27 Jun 2023 08:07
GSK gonorrhoea vaccine gets FDA fast track designation
(Sharecast News) - GSK said on Tuesday that its investigational vaccine for sexually transmitted infection gonorrhoea has been granted a fast track designation by the US Food and Drug Administration.
Read more27 Jun 2023 07:56
LONDON BRIEFING: Stocks called up; record profit for Telecom Plus
(Alliance News) - Stock prices in London were set to open higher on Tuesday, following a positive session for equities in Hong Kong and Shanghai.
Read more26 Jun 2023 08:38
TOP NEWS: GSK hails approvals for drug therapies in Japan and Europe
(Alliance News) - GSK PLC on Monday celebrated several regulatory approvals for new drug therapies, including treatments for shingles.
Read more26 Jun 2023 07:56
LONDON BRIEFING: Stocks firm; Aston Martin signs Lucid, Mercedes deals
(Alliance News) - Stocks in London were set to start the new week marginally lower, with financial markets unfazed by a failed revolt by a mercenary army in Russia over the weekend.
Read more26 Jun 2023 07:43
GSK gets an approval in Japan, a recommendation in Europe
(Sharecast News) - GSK announced two significant advancements on Monday, with the approval of an updated indication for Shingrix in Japan, as well as a positive opinion from the European Medicines Agency for daprodustat.
Read more23 Jun 2023 20:24
GSK soothes investors by settling first Zantac cancer lawsuit due for US trial
GSK shares best performer on London's stock market
*Read more23 Jun 2023 17:25
DIRECTOR DEALINGS: GSK CFO buys shares worth GBP321,500
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday and not separately reported by Alliance News:
Read more23 Jun 2023 17:21
European shares post worst week in three months, Siemens Energy slumps
Siemens Energy weighs on German stocks
*Read more23 Jun 2023 17:17
London stocks log sharp weekly declines as rate hike pressures mount
UK shoppers boost spending again in May
*Read more23 Jun 2023 16:58
LONDON MARKET CLOSE: Stocks end in the red as recession fears mount
(Alliance News) - Stocks in London closed lower on Friday as weak economic data and the prospect of global interests staying higher for longer put investors in a firmly risk-off mood.
Read more23 Jun 2023 12:41
The best-is-yet-to-come narrative fades
Euro zone business growth stalls in June -flash PMI
*Read more23 Jun 2023 12:09
LONDON MARKET MIDDAY: Housebuilders bear brunt of rate hike worries
(Alliance News) - Stock prices in London were lower heading into Friday afternoon, as a poor week for equities continued, with investors fretting over the prospect of central banks keeping interest rates higher for longer.
Read more23 Jun 2023 10:20
‘Dictator? That’S Absurd’: a guide for investors navigating U.S.-China tensions
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .
‘DICTATOR? THAT’S ABSURD’: A GUIDE FOR INVESTORS NAVIGATING U.S.-CHINA TENSIONS (0915 GMT)Read more23 Jun 2023 09:40
PMIs in focus as healthcare staves off deeper losses
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .
PMIS IN FOCUS, HEALTHCARE STAVES OFF DEEPER LOSSES (0840 GMT)Read more